Findings

What do systematic reviews say?

23 questions · 23 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 5 · 21.7%Very low 0 · 0%Low 18 · 78.3%Moderate 0 · 0%High 0 · 0%

Adverse effects (central nervous system) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (central nervous system) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 1.17 [0.77, 1.79]
1 study · 43 participants
Low

Adverse effects (behaviour) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (behaviour) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 0.95 [0.59, 1.55]
1 study · 43 participants
Low

Adverse effects (airways) · participants with epilepsy (BECTS)

Sulthiame may leads to higher adverse effects (airways) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 2.67 [1.17, 6.12]
1 study · 43 participants
Low